Table 3 Analysis of factors associated with empirical antipseudomonal use in pneumonia. Univariate and multivariate logistic regression analysis

Male sex

0.781 (0.520- 1.173)

0.234

1.971 (1.127- 3.446)

0.017

1.316 (0.660- 2.625)

0.436

ICU admission

0.155 (0.048- 0.503)

0.002

0.256 (0.076- 0.863)

0.028

4.608 (2.538- 8.368)

< 0.001

8.166 (3.691- 18.065)

< 0.0001

PSI risk class I-III vs IV/V

0.577 (0.384- 0.866)

0.008

0.595 (0.390- 0.907)

0.016

3.440 (1.770- 6.688)

< 0.001

1.817 (0.861- 3.834)

0.117

Multilobar involvement

0.457 (0.281- 0.744)

0.002

0.531 (0.319- 0.885)

0.015

1.676 (1.021- 2.752)

0.041

1.355 (0.732- 2.507)

0.333

 Liver disease

0.304 (0.107- 0.867)

0.026

0.413 (0.141- 1.214)

0.108

2.839 (1.412- 5.705)

0.003

1.808 (0.767- 4.261)

0.175

 Bronchiectasis

0.851 (0.311 -2.326)

0.753

1.629 (0.590- 4.499)

0.346

 Diabetes

1.179 (0.771 -1.802)

0.446

0.979 (0.579 -1.655)

0.936

 Chronic renal disease

1.354 (0.798 -2.299)

0.261

0.829 (0.407 -1685)

0.604

 Chronic heart disease

1.197 (0.737 -1.943)

0.468

1.078 (0.594 -1.954)

0.806

 No COPD

Reference category

Reference category

 GOLD I-III

1.061 (0.630-1.789)

0.823

0.987 (0.505-1.931)

0.971

0.790 (0.362-1.723)

0.553

 GOLD IV

1.146 (0.539-2.436)

0.720

3.415 (1.653-7.055)

0.001

2.993 (1.230-7.285)

0.016

Prior hospitalization

0.836 (0.518 -1.351)

0.464

5.579 (3.370- 9.237)

< 0.001

6.760 (3.017- 15.147)

< 0.0001

Nursing home residence

0.580 (0.265-1.267)

0.172

0.488 (0.171-1.394)

0.180

Prior antibiotic

0.897 (0.581 -1.385)

0.624

2.680 (1.645- 4.366)

< 0.001

1.058 (0.479- 2.366)

0.890

Immunocompromise

0.722 (0.439- 1.186)

0.199

3.021 (1.826- 4.999)

< 0.001

2.064 (1.135- 3.756)

0.018

Negative pneumoccocal antigen

3.768 (1.903- 7.459)

< 0.001

3.408 (1.696- 6.848)

0.001

0.754 (0.428- 1.326)

0.327